Central Venous Catheter Market Size, Share, & Trends Analysis | Global | 2025-2032 | Includes: Acute Central Venous Catheters, and Chronic Central Venous Catheters

Global Central Venous Catheter Market Report to 2032

The global central venous catheter market was valued at $1 billion in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.4%, reaching $1.1 billion by 2032.

This report covers the global market for central venous catheters (CVCs), including acute and chronic CVCs. Both categories include power-injectable and non-power-injectable devices.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by demographic factors, the rising burden of chronic disease, and increasing adoption of power-injectable CVCs. However, competition from PICCs and the high infection rate associated with CVC use continue to limit stronger growth.

Market Overview

The global central venous catheter market includes devices used to provide central venous access for medication delivery, chemotherapy, parenteral nutrition, dialysis-related care, critical care treatment, and long-term therapy.

The market includes acute and chronic CVCs. Acute CVCs are generally used in short-term hospital and critical care settings, while chronic CVCs support longer-term treatment needs. Both acute and chronic categories include power-injectable and non-power-injectable devices.

Power-injectable CVCs have become a dominant feature of the market and continue to shape value dynamics. These devices are increasingly preferred for patients with difficult venous access and in care settings where compatibility with contrast-enhanced imaging is important.

As power-injectable CVCs represent a larger share of total placements, their higher price point supports ASP stability and contributes to overall market value growth. This is important because the market is expected to grow modestly, with value supported more by product mix than by strong unit expansion.

Market Drivers

Demographic Factors

Demographic factors continue to support demand for central venous catheters. The world population is increasing at approximately 0.88% per year, creating a larger overall patient base requiring hospital care, infusion therapy, and critical care support.

CVCs are placed in patients of all ages, but they are more frequently used in elderly and pediatric patients. These groups often require reliable vascular access for complex treatment pathways, intensive care, or longer-term therapy.

As hospitalizations rise and more patients require advanced treatment, the number of units sold in the CVC market is expected to increase. This demographic base supports stable demand, even though competing vascular access products may limit stronger market expansion.

Growing Burden of Chronic Diseases

The growing burden of chronic disease is a major driver of CVC utilization. Increasing incidence of cancer, renal failure requiring dialysis, and advanced cardiovascular conditions creates a sustained need for central venous access.

CVCs play an important role in chemotherapy, parenteral nutrition, long-term medication delivery, and critical care treatment. These applications require reliable access and higher flow rates that may not always be achievable with substitute devices.

As chronic disease populations expand globally, CVC utilization is expected to grow steadily. This driver is especially important in developed markets with aging populations and in emerging markets where access to advanced treatment is improving.

Power-Injectable CVC Adoption

Power-injectable CVC adoption is supporting market value growth. These devices are designed to withstand higher pressures and can be used in contrast-enhanced imaging workflows.

Power-injectable CVCs are increasingly preferred in patients with difficult venous access because they provide flexibility across treatment and imaging needs. This can reduce the need for additional access placement and improve care efficiency.

Because power-injectable CVCs carry higher ASPs than non-power-injectable devices, their increased penetration supports overall ASP stability. This helps the market grow in value even when total unit expansion remains moderate.

Market Limiters

Use of Peripherally Inserted Central Catheters

The use of peripherally inserted central catheters has limited growth in the CVC market. In outpatient settings, PICCs have significantly lower infection rates than CVCs and can be used in many of the same cases.

PICCs can also be placed by nurses at the bedside, lowering costs and reducing procedural burden. This makes them attractive for patients who require central access but do not need the higher flow rates provided by CVCs.

However, CVCs remain indispensable in critical care because they offer higher flow rates than PICCs. In chronic care, CVCs are expected to face more competition from PICCs, and CVCs are often removed more quickly in order to be replaced with a PICC and then sometimes a PIVC.

High Infection Rate

CVCs have higher infection rates than substitute catheters. The financial costs and poor patient outcomes associated with catheter-related infections are strong limiters for CVC use.

Whenever possible, physicians prefer to place a catheter type with a lower infection rate. This can shift demand toward PICCs or other vascular access devices when clinically appropriate.

Antimicrobial CVCs partially address this issue, but CVCs will remain among the more infection-prone catheters in use. Infection risk will continue to influence device selection, care protocols, and adoption rates across both acute and chronic settings.

Training and Placement Considerations

CVC placement requires appropriate clinical skill, sterile technique, and ongoing catheter management. Improper placement or maintenance can increase the risk of complications, including infection and thrombosis.

As newer CVC technologies enter the market, training becomes even more important. Power-injectable devices, antimicrobial catheters, and specialized configurations may require staff familiarity to ensure correct use.

These requirements can limit adoption in facilities with fewer trained staff or limited vascular access resources. In emerging markets, training and infrastructure gaps may slow the adoption of premium CVC products.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers central venous catheters, including acute CVCs and chronic CVCs. Both categories include power-injectable and non-power-injectable devices.

Markets Covered and Segmentation

Central Venous Catheter Market

• Device type: Acute and chronic.

Acute CVCs are used primarily in hospital and critical care settings where short-term central venous access is needed. These devices support medication delivery, fluid administration, hemodynamic monitoring, and other care requirements where reliable central access is necessary.

Chronic CVCs are used for longer-term access needs, including chemotherapy, parenteral nutrition, and long-term medication delivery. These devices are important for patients who require repeated or extended access over time.

Power-injectable CVCs are available in both acute and chronic categories. These devices support high-pressure contrast injection and are increasingly preferred in care settings requiring compatibility with imaging workflows.

Non-power-injectable CVCs remain part of the market for standard central venous access needs. They may be used in cost-sensitive settings or when power injection is not required.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

Competitive Analysis

In 2025, Teleflex held the leading position in the global CVC market, dominating both the acute and chronic segments. Its leadership was established following the acquisition of Arrow International in 2007, which gave the company a comprehensive catheter product portfolio.

Teleflex entered the chronic CVC market in 2013 with the ARROW(R) JACC featuring Chlorag+ard(R) Technology, which offers antimicrobial and antithrombogenic properties suitable for both short-term and long-term use. The company primarily represents the triple-lumen subcategory of CVCs and has reported strong growth supported partly by increased CVC sales.

Becton Dickinson ranked as the second-leading competitor in the CVC market in 2025, largely due to its presence in the chronic CVC segment. BD's brands include PowerHohn(R), Hohn(R), PowerLine(R), PowerHickman(R), and Hickman(R) Trifusion(R) catheters.

These brands have become closely associated with chronic CVCs. Although the chronic CVC market has a declining growth rate, BD's established position and brand recognition support its significant market share.

B. Braun secured the third-leading position in the total CVC market in 2025 by focusing primarily on the acute CVC segment. Its Certofix(R) and Cavafix(R) product lines support its presence, while the Certofix(R) Protect line allows B. Braun to compete in the growing antimicrobial catheter segment.

Technology and Practice Trends

Power-Injectable CVC Penetration

Power-injectable CVCs are increasingly shaping market value. These devices support contrast-enhanced imaging and are preferred in patients who may require both central access and imaging compatibility.

Their higher ASPs support market value even when unit growth is modest.

Antimicrobial Catheters

Antimicrobial CVCs are an important response to infection risk. These products are designed to reduce catheter-related infections and improve patient outcomes.

Although they do not eliminate infection concerns, they help improve the clinical profile of CVCs.

Antithrombogenic Properties

Antithrombogenic CVC technologies are designed to reduce thrombus formation and related complications. These features may be important in both short-term and long-term use cases.

Products such as ARROW(R) JACC with Chlorag+ard(R) Technology reflect this trend.

Chronic CVC Brand Recognition

Chronic CVCs remain associated with established brands, especially in long-term therapy markets. Brand familiarity matters because physicians and hospitals often rely on trusted products for complex access needs.

This supports incumbent competitors with established portfolios.

PICC Competition

PICCs continue to compete with CVCs in outpatient and chronic care settings. Their lower infection rates and bedside placement advantages make them attractive substitutes in many cases.

CVCs remain important in critical care because of higher flow requirements.

Infection Prevention Focus

Infection prevention remains central to CVC practice. Hospitals continue to focus on sterile insertion, catheter maintenance, antimicrobial products, and replacement protocols.

This trend will continue shaping product development and clinical use.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global central venous catheter market today, and how much is it expected to grow through 2032?
• How are acute and chronic CVC segments performing across the forecast period?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role do power-injectable CVCs play in supporting ASP stability?
• How is the growing burden of cancer, renal failure, and cardiovascular disease affecting CVC utilization?
• Why do CVCs remain important in critical care despite competition from PICCs?
• How do infection risks affect product selection and market growth?
• What role do antimicrobial and antithrombogenic technologies play in CVC adoption?
• Which companies lead the global CVC market?
• How are Teleflex, BD, and B. Braun positioned across acute, chronic, antimicrobial, and power-injectable CVC categories?

The Global Central Venous Catheter Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand power-injectable adoption, and support commercial planning in the global CVC market.